Section
The MI-SIGHT telemedicine program significantly improves vision and eye health outcomes by providing glaucoma and eye disease screening with care navigation in community health centers, demonstrating high satisfaction and cost-effectiveness
A large UK Biobank study demonstrates that poor sleep, low physical activity, and high sedentary behavior independently and jointly increase cataract risk, with lifestyle modifications reducing incidence.
A large retrospective study found that diabetic patients using metformin for at least five consecutive years have a significantly lower risk of developing age-related macular degeneration, especially the dry type.
UCLA engineers and ophthalmologists mapped segmental, task-dependent activation of the orbicularis oculi during five closure behaviors, defining a roadmap for targeted neurostimulation to restore protective blinking in patients with eyelid
Alcon introduces Tryptyr, the first TRPM8 agonist eye drop, promising rapid tear production for dry eye disease. FDA-approved in May 2024 following robust phase 3 trials.
The FDA has approved Vizz, a once-daily aceclidine ophthalmic solution, for presbyopia in adults based on robust phase 3 data. The eye drop offers up to 10 hours of improved near vision with a favorable safety profile.
Veligrotug demonstrates robust efficacy and manageable safety in both active and chronic thyroid eye disease, positioning itself as a potential alternative to teprotumumab based on phase 3 THRIVE trial data.
GLP-1 receptor agonist use, especially liraglutide, is associated with a higher risk of nonarteritic anterior ischemic optic neuropathy (NAION) during the first year, particularly in patients without diabetes or obesity.
